Literature DB >> 215529

Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas.

G de-The, M F Lavoue, L Muenz.   

Abstract

In order to assess the differences in serological reactivities of NPC patients from high, intermediate and low incidence areas, 288 NPC sera from Hong Kong, Singapore, Tunis, East Africa, Paris and Los Angeles, together with sera from patients with ear, nose and throat tumours other than NPC and with those from normal individuals from the same areas, were tested 'blind' with the same batches of antigen. Important differences (up to 3-fold) in the GMTs of antibodies directed against VCA, EA and EBNA were observed between different ethnic groups. Although the stages of the disease varied somewhat between groups, the main cause of the variations appeared to lie in the socio-economic environment of the patients. Apart from these variations, and regardless of geographical or ethnic origins, NPC was consistently found to be associated with an active infection (or reactivation) by Epstein-Barr virus, which was not the case for patients with other tumours or for normal individuals from the same areas or of the same ethnic groups.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 215529

Source DB:  PubMed          Journal:  IARC Sci Publ


  11 in total

Review 1.  Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.

Authors:  T Ooka; M de Turenne-Tessier; M C Stolzenberg
Journal:  Springer Semin Immunopathol       Date:  1991

2.  Identification of a Novel, EBV-Based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.

Authors:  Allan Hildesheim; Denise L Doolan; Anna E Coghill; Ruth M Pfeiffer; Carla Proietti; Wan-Lun Hsu; Yin-Chu Chien; Lea Lekieffre; Lutz Krause; Andy Teng; Jocelyn Pablo; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Zhiwei Liu; Chien-Jen Chen; Jaap Middeldorp; Jason Mulvenna; Jeff Bethony
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

3.  Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.

Authors:  Anna E Coghill; Wan-Lun Hsu; Ruth M Pfeiffer; Hedy Juwana; Kelly J Yu; Pei-Jen Lou; Cheng-Ping Wang; Jen-Yang Chen; Chien-Jen Chen; Jaap M Middeldorp; Allan Hildesheim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-04-27       Impact factor: 4.254

Review 4.  Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus.

Authors:  C Boshoff; R A Weiss
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

5.  Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.

Authors:  Kelly J Yu; Wan-Lun Hsu; Ruth M Pfeiffer; Chun-Ju Chiang; Cheng-Ping Wang; Pei-Jen Lou; Yu-Juen Cheng; Patti Gravitt; Scott R Diehl; Alisa M Goldstein; Chien-Jen Chen; Allan Hildesheim
Journal:  Clin Cancer Res       Date:  2011-03-29       Impact factor: 12.531

Review 6.  Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature.

Authors:  Anna E Coghill; Allan Hildesheim
Journal:  Am J Epidemiol       Date:  2014-08-28       Impact factor: 4.897

7.  Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.

Authors:  Shih-Hsin Chiu; Chung-Chun Wu; Chih-Yeu Fang; Shu-Ling Yu; Hui-Yu Hsu; Yen-Hung Chow; Jen-Yang Chen
Journal:  Oncotarget       Date:  2014-09-30

8.  Epstein-Barr virus in nasopharyngeal and salivary gland carcinomas of Greenland Eskimoes.

Authors:  A K Saemundsen; H Albeck; J P Hansen; N H Nielsen; M Anvret; W Henle; G Henle; K A Thomsen; H K Kristensen; G Klein
Journal:  Br J Cancer       Date:  1982-11       Impact factor: 7.640

9.  Risk factors for high anti-HHV-8 antibody titers (> or =1:51,200) in black, HIV-1 negative South African cancer patients: a case control study.

Authors:  Janet M Wojcicki; Rob Newton; Margaret I Urban; Lara Stein; Martin Hale; Moosa Patel; Paul Ruff; Ranjan Sur; Dimitra Bourboulia; Freddy Sitas
Journal:  BMC Infect Dis       Date:  2003-09-12       Impact factor: 3.090

10.  Virus-encoded microRNA contributes to the molecular profile of EBV-positive Burkitt lymphomas.

Authors:  Pier Paolo Piccaluga; Mohsen Navari; Giulia De Falco; Maria Raffaella Ambrosio; Stefano Lazzi; Fabio Fuligni; Cristiana Bellan; Maura Rossi; Maria Rosaria Sapienza; Maria Antonella Laginestra; Maryam Etebari; Emily A Rogena; Lynnette Tumwine; Claudio Tripodo; Davide Gibellini; Jessica Consiglio; Carlo M Croce; Stefano A Pileri; Lorenzo Leoncini
Journal:  Oncotarget       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.